Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regulus Therapeutics

8.16
0.0000
Volume:- -
Turnover:75.91M
Market Cap:564.95M
PE:-11.28
High:8.16
Open:8.16
Low:8.16
Close:8.16
Loading ...

BRIEF-Novartis Completes Acquisition Of Regulus Therapeutics

Reuters
·
25 Jun

Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary

Reuters
·
25 Jun

Novartis' Tender Offer for Regulus Therapeutics Expires with 74.49% Shareholder Acceptance

Reuters
·
25 Jun

Novartis AG Announces Expiration of Antitrust Waiting Period for Regulus Therapeutics Acquisition

Reuters
·
23 Jun

Preston Klassen, President & Head of R&D, Reports Acquisition of Common Shares in Regulus Therapeutics Inc

Reuters
·
05 Jun

Novartis Ag - Novartis Announces Commencement of Tender Offer to Acquire Regulus Therapeutics

THOMSON REUTERS
·
27 May

Novartis Launches Tender Offer to Acquire Regulus Therapeutics for $7.00 Per Share Plus Contingent Value Right

Reuters
·
27 May

Novartis Ag - Offer Includes $7.00 Cash per Share Plus Contingent Value Right

THOMSON REUTERS
·
27 May

Novartis Ag - Offer Subject to Customary Conditions Including Hart-Scott-Rodino Act

THOMSON REUTERS
·
27 May

Novartis Ag - Offer to Expire on June 24, 2025

THOMSON REUTERS
·
27 May

Regulus Resources Inc. Unveils Corporate Presentation Highlighting AntaKori Copper-Gold Project and Long-Term Strategy

Reuters
·
21 May

Regulus Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate

Benzinga
·
09 May

Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Regulus Therapeutics Reports Increased R&D and G&A Expenses in Q1 2025; Cash Runway Extends to Early 2026

Reuters
·
09 May

Regulus Therapeutics Q1 Basic EPS USD -0.15

THOMSON REUTERS
·
09 May

Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
06 May

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

LA Times
·
02 May

Biotech Alert: Searches spiking for these stocks today

TipRanks
·
02 May

Regulus Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
01 May

Oppenheimer Downgrades Regulus Therapeutics to Market Perform From Outperform

MT Newswires Live
·
01 May